Unknown

Dataset Information

0

The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy.


ABSTRACT: Cancer immunotherapy and tumor microenvironment have been at the forefront of research over the past decades. Targeting immune checkpoints especially programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) has made a breakthrough in treating advanced malignancies. However, the low response rate brings a daunting challenge, changing the focus to dig deeply into the tumor microenvironment for alternative therapeutic targets. Strikingly, the inhibitory immune checkpoint lymphocyte activation gene-3 (LAG-3) holds considerable potential. LAG-3 suppresses T cells activation and cytokines secretion, thereby ensuring immune homeostasis. It exerts differential inhibitory impacts on various types of lymphocytes and shows a remarkable synergy with PD-1 to inhibit immune responses. Targeting LAG-3 immunotherapy is moving forward in active clinical trials, and combination immunotherapy of anti-LAG-3 and anti-PD-1 has shown exciting efficacy in fighting PD-1 resistance. Herein, we shed light on the significance of LAG-3 in the tumor microenvironment, highlight its role to regulate different lymphocytes, interplay with other immune checkpoints especially PD-1, and emphasize new advances in LAG-3-targeted immunotherapy.

SUBMITTER: Long L 

PROVIDER: S-EPMC6305110 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy.

Long Long L   Zhang Xue X   Chen Fuchun F   Pan Qi Q   Phiphatwatchara Pronnaphat P   Zeng Yuyang Y   Chen Honglei H  

Genes & cancer 20180501 5-6


Cancer immunotherapy and tumor microenvironment have been at the forefront of research over the past decades. Targeting immune checkpoints especially programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) has made a breakthrough in treating advanced malignancies. However, the low response rate brings a daunting challenge, changing the focus to dig deeply into the tumor microenvironment for alternative therapeutic targets. Strikingly, the inhibitory immune checkpoint lymphocyte activation ge  ...[more]

Similar Datasets

| S-EPMC9361790 | biostudies-literature
| S-EPMC7896069 | biostudies-literature
| S-EPMC10899349 | biostudies-literature
| S-EPMC7491111 | biostudies-literature
| S-EPMC10502727 | biostudies-literature
| S-EPMC8529050 | biostudies-literature
| S-SCDT-EMM-2021-14502 | biostudies-other
| S-EPMC8356190 | biostudies-literature
| S-EPMC10377063 | biostudies-literature
| S-EPMC9274752 | biostudies-literature